share_log

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5:募资说明书
美股SEC公告 ·  2024/09/10 04:06

Moomoo AI 已提取核心信息

Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $50,000,000. This update, detailed in a prospectus supplement filed on September 9, 2024, follows the company's public float exceeding $75.0 million on May 2, 2024, which lifted previous sales limitations under General Instruction I.B.6 of Form S-3. As of the filing date, Allarity Therapeutics has already sold 41,801,224 shares for gross proceeds of $29,998,138. The prospectus supplement amends the prior prospectus dated November 29, 2023, and the subsequent supplement dated March 19, 2024. Investors are cautioned that investing in Allarity's common stock involves high risk, and they should review the risk factors detailed in the March 19, 2024, prospectus supplement and other referenced documents.
Allarity Therapeutics Inc. has announced an amendment to its Sales Agreement with Ascendiant Capital Markets, LLC, increasing the total amount of common stock it may offer and sell to $50,000,000. This update, detailed in a prospectus supplement filed on September 9, 2024, follows the company's public float exceeding $75.0 million on May 2, 2024, which lifted previous sales limitations under General Instruction I.B.6 of Form S-3. As of the filing date, Allarity Therapeutics has already sold 41,801,224 shares for gross proceeds of $29,998,138. The prospectus supplement amends the prior prospectus dated November 29, 2023, and the subsequent supplement dated March 19, 2024. Investors are cautioned that investing in Allarity's common stock involves high risk, and they should review the risk factors detailed in the March 19, 2024, prospectus supplement and other referenced documents.
Allarity Therapeutics Inc.宣布与Ascendiant Capital Markets, LLC的销售协议进行了修订,增加了其可以提供和出售的普通股总额达到5000万美元。此更新详细说明于2024年9月9日提交的招股说明书补充说明之中,后者基于公司于2024年5月2日的公开流通量超过7500万美元,在此之下,解除了根据S-3表格的第I.b.6通用说明的之前销售限制。截至提交日期,Allarity Therapeutics已经出售了41,801,224股,总收入为29,998,138美元。这份招股说明书的修正版本修订了之前于2023年11月29日发布的招股说明书,以及之后的于2024年3月19日发布的招股说明书。投资者被告知投资于Allarity的普通股涉及较高的风险,他们应该审查于2024年3月19日的招股说明书以及其他引用的文件中详细列出的风险因素。
Allarity Therapeutics Inc.宣布与Ascendiant Capital Markets, LLC的销售协议进行了修订,增加了其可以提供和出售的普通股总额达到5000万美元。此更新详细说明于2024年9月9日提交的招股说明书补充说明之中,后者基于公司于2024年5月2日的公开流通量超过7500万美元,在此之下,解除了根据S-3表格的第I.b.6通用说明的之前销售限制。截至提交日期,Allarity Therapeutics已经出售了41,801,224股,总收入为29,998,138美元。这份招股说明书的修正版本修订了之前于2023年11月29日发布的招股说明书,以及之后的于2024年3月19日发布的招股说明书。投资者被告知投资于Allarity的普通股涉及较高的风险,他们应该审查于2024年3月19日的招股说明书以及其他引用的文件中详细列出的风险因素。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息